<DOC>
	<DOCNO>NCT01155453</DOCNO>
	<brief_summary>This open label , dose finding , phase Ib clinical trial determine maximum tolerate dose ( MTD ) /or recommend phase II dose ( RP2D ) schedule PI3K ( Phosphatidylinositol 3-Kinase ) inhibitor BKM120 give combination MEK inhibitor GSK1120212 patient select , advance solid tumor . The focus tumor RAS/RAF mutation triple negative breast cancer . Both study drug administer daily orally continuous schedule , treatment cycle define 28 day . Cohorts least 3 maximum 6 patient eligible dose-determining set enrol per dose combination MTD . The MTD define high drug dosage cause first cycle treatment medically unacceptable , dose-limiting toxicity ( DLT ) 33 % treat patients.. At least 12 patient require MTD 6 patient RP2D level allow evaluation combination 's safety pharmacokinetics pharmacodynamics . Upon declaration MTD and/or RP2D , patient enrol expansion part study , assess safety , well learn efficacy study drug combination . - Expansion Arm 1 consist approximately 15 patient RAS BRAF mutant advance NSCLC - Expansion Arm 2 consist approximately 15 patient RAS BRAF-mutant ovarian cancer - Expansion Arm 3 consist approximately 15 patient RAS BRAF-mutant pancreatic cancer</brief_summary>
	<brief_title>A Study Investigate Safety , Pharmacokinetics ( PK ) Pharmacodynamics ( PD ) BKM120 Plus GSK1120212 Selected Advanced Solid Tumor Patients</brief_title>
	<detailed_description />
	<mesh_term>Trametinib</mesh_term>
	<criteria>histologically/ cytologically confirm , advance non resectable solid tumor Measurable nonmeasurable , evaluable disease determine RECIST 1.0 Patients primary Central Nervous System ( CNS ) tumor CNS tumor involvement . Clinically manifest diabetes mellitus Unacceptable ocular/retinal condition Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>BKM120</keyword>
	<keyword>RAS RAF mutation ,</keyword>
	<keyword>triple negative breast cancer ,</keyword>
	<keyword>pancreatic cancer ,</keyword>
	<keyword>PI3K inhibitor ,</keyword>
	<keyword>MEK inhibitor</keyword>
</DOC>